SHLTN.SW up 7.27% pre-market 12 Jan 2026: top gainer, watch CHF1.34 target
SHLTN.SW stock led Swiss pre-market gainers on 12 Jan 2026 after a 7.27% jump to CHF 1.18 on the SIX exchange. Trading volume rose to 78,716 shares versus a 20,820 average, signalling stronger interest in SHL Telemedicine Ltd. (SHLTN.SW) ahead of regular hours. The move follows recent technical strength and renewed investor attention to telemedicine devices. We review drivers, valuation, risks, and short-term targets to explain why SHL Telemedicine appears among top gainers today.
Price action and immediate drivers for SHLTN.SW stock
SHL Telemedicine Ltd. (SHLTN.SW) opened pre-market at CHF 1.18, up 0.08 from the previous close. The intraday band shows a day high CHF 1.20 and day low CHF 1.18, with a one-day percentage change of 7.27%. Volume spiked to 78,716 versus an average of 20,820, a >3.7x lift, consistent with top-gainer flows.
The short-term move tracks a mix of technical support near the 50-day average (CHF 1.07) and headlines around clinical collaborations and device uptake. Sector momentum in Healthcare on the SIX is muted, so the stock-specific volume is a key driver.
Fundamentals and valuation snapshot for SHL Telemedicine Ltd.
SHLTN.SW trades at CHF 1.18 with a market capitalisation near CHF 18.69 million and 16,390,977 shares outstanding. Price-to-sales is 0.41, price-to-book is 0.60, and trailing EPS is negative at -0.76, producing a negative P/E. These metrics point to a low valuation relative to peers but reflect consistent net losses.
Cash per share is CHF 0.81 and book value per share is CHF 2.36. Current ratio 0.87 flags working capital pressure. Investors should weigh attractive valuation ratios against operating losses and thin liquidity.
Technical picture and trading signals
Technical indicators show a neutral-to-mildly bullish setup for SHLTN.SW. RSI is 51.50, MACD histogram is 0.01, and Stochastic %K is 71.60, suggesting limited overbought risk. Bollinger middle band sits at CHF 1.09 with upper at CHF 1.23, placing current price close to the upper band.
Momentum readings show ROC 4.59% and MFI 73.93, indicating strong recent buying but not extreme readings. ADX 8.05 suggests no strong trend yet, so price moves may remain choppy.
Meyka AI stock grade and analyst context for SHLTN.SW
Meyka AI rates SHLTN.SW with a score of 65.75 out of 100 — Grade: B, Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The grade balances low valuation metrics and cash buffers against recurring net losses and modest revenue growth.
This scoring is informational and not financial advice. The company’s collaborations with Mayo Clinic and academic partners support product validation, but commercial scale and consistent profitability remain the main hurdles.
Catalysts, risks and sector context
Key near-term catalysts include clinical trial updates, regulatory news on SmartHeart devices, and quarterly results (next earnings date noted as 22 Apr 2026). Positive trial readouts or new distributor agreements would likely support higher prices.
Principal risks are thin liquidity on SIX, negative trailing EPS (-0.76), a current ratio below 1 (0.87), and sector headwinds in Healthcare where Swiss peers trade at higher multiples (average PB ~4.52). Currency exposure (ILS operational base, CHF listing) and reimbursement dynamics are additional risks.
Price targets, forecasts and trading plan
Meyka AI’s forecast model projects monthly CHF 1.17, quarterly CHF 1.34, and yearly CHF 1.11 for SHLTN.SW. The quarterly figure implies an upside of 13.56% from the current CHF 1.18, while the yearly projection implies downside of -6.01%.
For traders, a short-term plan is to watch CHF 1.23–1.34 as upside targets and use CHF 1.07 (50-day average) as a technical support stop. For investors, horizon, cash runway, and successful commercial rollouts should guide sizing.
Final Thoughts
Key takeaways for SHLTN.SW stock: the listing on SIX moved up 7.27% pre-market to CHF 1.18 on 12 Jan 2026, led by higher volume and technical support near the 50-day average. Valuation reads cheap by price-to-sales (0.41) and price-to-book (0.60), but persistent net losses (EPS -0.76) and a current ratio of 0.87 mean operational risk is material. Meyka AI’s forecast model projects a quarterly target of CHF 1.34 (implied +13.56%) and a one-year projection of CHF 1.11 (implied -6.01%). Forecasts are model-based projections and not guarantees. Given the mix of low multiples, ongoing clinical validation, and liquidity constraints, our view is that SHL Telemedicine (SHLTN.SW) suits risk-aware investors or tactical traders watching catalysts. We track upcoming earnings and clinical updates as the primary triggers for a sustained move higher. For more data and live tools see the SHL Telemedicine website and our Meyka stock page for SHLTN.SW at Meyka.
FAQs
What drove SHLTN.SW stock higher pre-market today?
The pre-market gain to CHF 1.18 (+7.27%) was driven by a volume spike to 78,716 shares, technical support near the 50-day average, and renewed interest in device validation news.
What are the main valuation metrics for SHLTN.SW?
Key metrics: price-to-sales 0.41, price-to-book 0.60, EPS -0.76, cash per share CHF 0.81. These show low multiples but continued losses.
How does Meyka AI view SHLTN.SW stock?
Meyka AI rates SHLTN.SW 65.75/100 (Grade B, HOLD). This factors in benchmark and sector comparison, growth, key metrics, and analyst context. Not advice.
What is the short-term price forecast for SHLTN.SW?
Meyka AI’s model projects a quarterly target of CHF 1.34, implying +13.56% vs CHF 1.18. Forecasts are projections and not guarantees of performance.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
